Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts. (Q39654818)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20848284%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20848284%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20848284%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20848284%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Giovanni Scambia

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20848284%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Andrea Fattorossi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20848284%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Ilaria De Stefano

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20848284%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Gian Franco Zannoni

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20848284%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Maria Grazia Prisco

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20848284%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Daniele Travaglia

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20848284%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Silvia Baroni

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20848284%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Davide Renier

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20848284%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Daniela Gallo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20848284%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

publication date

17 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20848284%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

14 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20848284%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20848284%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20848284%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

107-116

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20848284%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1462-2

Estimates of the cancer incidence and mortality in Europe in 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1462-2

The promise and perils of 'targeted therapy' of advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1462-2

Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1462-2

Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1462-2

Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1462-2

Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1462-2

Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1462-2

Liposome-based approaches to overcome anticancer drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1462-2

HA receptors: regulators of signalling to the cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1462-2

Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1462-2

Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1462-2

Design, synthesis and applications of hyaluronic acid-paclitaxel bioconjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1462-2

CD44 isoforms in normal and leukemic hematopoiesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1462-2

Adhesion receptors on haematopoietic progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1462-2

A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1462-2

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1462-2

Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1462-2

Normal structure, function, and histology of mucosa-associated lymphoid tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1462-2

Models of ovarian cancer--are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1462-2

Murine erythropoietic impairment induced by paclitaxel: interactions of GATA-1 and erythroid Krüppel-like transcription factors, apoptotic related proteins and erythropoietin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1462-2

Adhesive interactions in hemopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1462-2